Form 4: LeMaitre Vascular CEO George W. LeMaitre Reports Stock Sales and Option Exercises

George W. LeMaitre, Chairman and CEO of LeMaitre Vascular, Inc., reported multiple transactions involving the company's common stock, including sales and option exercises, between May 16 and May 20, 2025.

Summary

• George W. LeMaitre, the Chairman and CEO of LeMaitre Vascular, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On May 16, 2025, LeMaitre sold 18,733 shares of common stock at a weighted average price of $84.7661 per share, resulting in 1,873,651 shares beneficially owned.
• On May 19, 2025, he sold 71,168 shares at a weighted average price of $85.8557 and 5,700 shares at $84.9395, leaving him with 1,796,783 shares.
• On May 20, 2025, LeMaitre exercised options to acquire a total of 34,619 shares at prices ranging from $35.48 to $54.65.
• Also on May 20, 2025, he sold 3,300 shares at a weighted average price of $85.2416 and 1,099 shares at $84.6926.
• Following these transactions, LeMaitre's beneficially owned shares totaled 1,827,003.
• The exercised options were granted at various dates and vest over four or five-year periods.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While option exercises are generally positive, the significant stock sales offset this, creating uncertainty. The market's reaction will depend on how it interprets the CEO's motivations.

Positives

• The exercise of stock options indicates confidence in the company's future performance, as the CEO is willing to acquire more shares.

Negatives

• The sale of a significant number of shares by the CEO could be interpreted negatively by investors, potentially signaling a lack of confidence or a need for personal liquidity.

Risks

• Large sales of stock by insiders can create downward pressure on the stock price.
• The market may react negatively to the CEO's stock sales, regardless of the underlying reason.

Industry Context

Insider transactions are common in publicly traded companies and are closely monitored by investors for signals about a company's prospects. The timing and size of these transactions can influence market sentiment.

Comparison to Industry Standards

• Comparing LeMaitre's insider trading activity to companies like Edwards Lifesciences or Medtronic would provide context.
• Analyzing the ratio of insider sales to purchases across the medical device industry could reveal whether LeMaitre's activity is typical.
• Benchmarking the vesting schedules of LeMaitre's stock options against industry norms would be useful.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially affecting the stock price.
• Employees may be concerned about the CEO's confidence in the company.
• The transactions could influence investor perception of the company's financial health.

Key Dates

Keywords

LeMaitre Vascular, LMAT, George LeMaitre, stock sale, option exercise, Form 4, insider trading, beneficial ownership